Who Created Oxycodone
The German pharmaceutical company Bayer first synthesized oxycodone in 1916 as a semi-synthetic opioid derived from thebaine. The goal was to develop a painkiller with strong efficacy but a potentially lower abuse profile than existing opioids. Early marketing positioned it as a less addictive alternative to morphine and codeine, a claim that later proved controversial. The molecule was patented and introduced under the brand name Eukodal in several European markets before spreading globally. Today, oxycodone remains one of the most prescribed opioids worldwide, with millions of prescriptions dispensed annually in the United States alone history of oxycodone and the opioid crisis.
OxyContin and Purdue Pharma
The Role of Purdue Pharma
Purdue Pharma, owned by the Sackler family, introduced OxyContin in 1996 as a long-acting oxycodone formulation. The company aggressively marketed it for moderate to severe pain, claiming the controlled-release mechanism reduced abuse potential. Internal documents later revealed Purdue was aware of the high abuse and addiction risks yet continued to promote the drug. OxyContin became a blockbuster product, generating billions in annual revenue and making Purdue one of the most profitable pharmaceutical companies in the U.S. SEC filings on Purdue Pharma.
Legal and Financial Consequences
Purdue Pharma filed for bankruptcy in 2019 amid thousands of lawsuits from states, cities, and individuals alleging deceptive marketing practices. The company agreed to a settlement framework that includes billions of dollars in payouts to state and local governments over the opioid crisis. The Sackler family faced personal lawsuits and settlements requiring the surrender of significant personal wealth. The U.S. Department of Justice and state attorneys general continue to negotiate final terms of the bankruptcy plan. The case has become a landmark in corporate accountability for pharmaceutical marketing practices Forbes coverage on Purdue and opioids.
Current Market and Manufacturers
Generic Oxycodone and Global Production
After the OxyContin patent expired, multiple generic manufacturers began producing oxycodone hydrochloride tablets. Today, oxycodone is marketed under numerous brand names and as generic drugs by companies such as Teva, Amneal, and Dr. Reddy's Laboratories. The U.S. Drug Enforcement Administration strictly regulates oxycodone as a Schedule II controlled substance due to its high potential for abuse and dependence. Global production is concentrated among a small number of licensed pharmaceutical firms that must comply with manufacturing and distribution controls. Annual prescription volumes remain high, with oxycodone consistently ranking among the most dispensed opioid analgesics in the United States SEC filings on pharmaceutical companies.
Regulatory Oversight and Distribution
The Food and Drug Administration approves new oxycodone formulations and generics based on bioequivalence and manufacturing standards. The DEA sets annual manufacturing quotas for oxycodone to limit supply and curb diversion. Wholesale distributors such as McKesson, AmerisourceBergen, and Cardinal Health play a central role in the distribution chain, facing ongoing litigation over their role in opioid dispersal. State prescription drug monitoring programs track oxycodone dispensing to identify unusual prescribing patterns. Regulatory reforms continue to tighten prescribing rules, packaging requirements, and patient risk assessment protocols